Anticoagulants and Immunosuppressives in Behçet’s Syndrome
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn:
”Anticoagulants and immunosuppressive therapy for thrombosis in Behçet’s syndrome: a systematic review and meta-analysis
By Arisa Chuklin, Thita Joy Chiasakul, and Noppacharn Uaprasert
• Context: Behçet’s syndrome is a systemic vasculitis often complicated by venous or arterial thrombosis, yet the optimal role of anticoagulation remains uncertain.
• Study: Across 20 studies (315 patients with disaggregated data), this meta-analysis compared relapse rates under immunosuppressives, anticoagulants, or both.
• Findings: Combination therapy markedly reduced thrombosis relapse (17.7%) versus immunosuppressives alone (43.7%) or anticoagulants alone (54.9%), supporting a dual-modality approach for vascular Behçet’s.”
Title: Anticoagulants and immunosuppressive therapy for thrombosis in Behçet’s syndrome: a systematic review and meta-analysis
Authors: Arisa Chuklin, Thita Chiasakul, Noppacharn Uaprasert
Read the article here.
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 16, 2026, 06:05Wolfgang Miesbach on Jacob Lund’s Study: How to Define FVIII Bioequivalence
-
Jan 16, 2026, 05:52Piotr Czempik Shares His Latest Contribution to Acta Haematologica Polonic
-
Jan 16, 2026, 05:44Florian Piekarski on Perioperative Blood Management When Allogeneic Transfusion is Not Aaccepted
-
Jan 16, 2026, 05:00Plaque Rupture and Thrombosis
-
Jan 16, 2026, 04:52Arterial Disease Across Vascular Beds․ Lipoprotein(a) as a Causal Risk Factor
-
Jan 16, 2026, 04:51Higher-Dose Clotting Factor Prophylaxis Does Not Reduce Postpartum Hemorrhage in Women with von Willebrand Disease
-
Jan 16, 2026, 04:48Reza Shojaei on Plasma Donation as Life-Changing Medicine in Motion
-
Jan 16, 2026, 04:11Open-Label Extension Study of Marstacimab: Pfizer Has Reported a Fatal Event
-
Jan 16, 2026, 04:11Why is DVT More Common In the Left Leg? Dr Raheel Moazzam’s New Study Gives Answers!